Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dibenzepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | HTR6 | P50406 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HEXA | P06865 | 1/20 | 0.55 |
| ▸ | HEXB | P07686 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibenzepin SCHEMBL29354805 | 1.00 | HRH1 (1.00) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL668219 | 0.98 | HRH1 (0.97) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL29375228 | 0.98 | HRH1 (0.97) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL14973430 | 0.97 | HRH1 (0.94) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dimetacrine SCHEMBL28221926 | 0.84 | HRH1 (0.71) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL11746213 | 0.84 | HRH1 (0.72) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL29492639 | 0.83 | HRH1 (0.69) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL28086113 | 0.82 | HRH1 (0.68) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL30839875 | 0.81 | HEXA (0.72) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL13590076 | 0.81 | HEXA (0.72) | HRH1DRD2HTR6SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3833 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636509-B1 | Pharmacological wearable cardioverter defibrillator (WCD) | Rottenberg, Eric Marc (US) | 2026-05-26 | — | — | US | claimed |
| EP-4706649-A1 | USE OF ADRENALIN FOR THE TREATMENT OF SHOCKS | BIOPROJET (FR) | 2026-03-11 | — | — | EP | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| US-12496300-B2 | Methods of treating acute depression and anxiety | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-12-16 | — | — | US | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-12263178-B2 | Pharmaceutical compositions and methods | POP TEST ONCOLOGY LLC (US) | 2025-04-01 | — | — | US | claimed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| US-6080426-A | Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process | WARNER-LAMBERG COMPANY (US) | 2000-06-27 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| CN-1215322-A | Method for encapsulating caplets in capsules and solid dosage forms obtainable by this method | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | CN | claimed |
| EP-0891180-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1999-01-20 | — | — | EP | claimed |
| CN-1170346-A | Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process | WARNER LAMBERT CO (US) | 1998-01-14 | — | — | CN | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| WO-1997037629-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | claimed |
| EP-0797424-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-01 | — | — | EP | claimed |
| WO-1996018370-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |